A Phase 2 interventional study of MenABCWY and Bivalent rLP2086 (60-µg Dose) in Meningococcal Vaccine, sponsored by Pfizer. Terminated at 21 sites in 3 countries. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
Biological: MenABCWY · Drug: Prophylactic Liquid Paracetamol (PLP)
Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
Biological: MenABCWY
Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Pracetamol (SLP) during primary vaccinations.
Biological: Bivalent rLP2086 (60-µg Dose) · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix · Drug: Scheduled Liquid Paracetamol (SLP)
Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
Biological: Bivalent rLP2086 (60-µg Dose) · Biological: Nimenrix
Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
Biological: Bivalent rLP2086 (120-µg Dose) · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix
Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.
Biological: MenABCWY · Drug: Scheduled Liquid Paracetamol (SLP)
Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
Biological: Bexsero · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix
Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
Biological: Bexsero · Biological: Nimenrix
Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.
Biological: MenABCWY · Drug: Therapeutic Liquid Paracetamol (TLP)
Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.
Biological: MenABCWY · Other: Placebo · Drug: Scheduled Liquid Paracetamol (SLP) · Drug: Therapeutic Liquid Paracetamol (TLP)
Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.
Biological: Bexsero · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix · Drug: Therapeutic Liquid Paracetamol (TLP)
Neisseria meningitis groups A, B, C W, and Y vaccine
Trumenba (half dose) - Meningococcal Group B vaccine
Trumenba - Meningococcal Group B vaccine
Bexsero - Meningococcal Group B vaccine
PLP administration during primary vaccinations 1 and 2
Nimenrix - Meningococcal Group A, C, W and Y vaccine
Normal Saline
SLP administration after primary vaccinations 1 and 2.
TLP administration after primary vaccinations 1 and 2
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=LLOQ for Each MenA, MenC, MenW and MenY Test Strains 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participants achieving hSBA titer greater than or equal to (\>=) lower limit of quantitation (LLOQ) (i.e.,1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided confidence interval (CI) using the Clopper and Pearson method was presented. Analysis was performed on Post-primary vaccination 2 (post-PV2) evaluable immunogenicity population (EIP). No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.
Time frame: 1 month after primary vaccination 2
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenACWY MenA, MenC, MenW and MenY Test Strains 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participants achieving hSBA titer \>= LLOQ (1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.
Time frame: 1 month after booster vaccination
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.
Time frame: 1 month After primary vaccination 2
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 3 and 4 Combined Versus Group 5
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain(1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented.
Time frame: 1 month after primary vaccination 2
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.
Time frame: 1 Month after booster vaccination
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Groups 3, 4 and 5
Percentage of participants achieving hSBA titer \>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. Groups 4 and 5 had no serum samples collected post-booster for serology testing due to study termination.
Time frame: 1 Month after booster vaccination
Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after primary vaccination 1
Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 Days after primary Vaccination 2
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method
Time frame: Within 7 Days after primary Vaccination 1
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness was graded as Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after primary vaccination 2
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Medically attended adverse event (MAE) was defined as a nonserious AE that resulted in an evaluation at a medical facility. Newly diagnosed chronic medical condition (NDCMC) was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Within 30 days after primary vaccination 1
Percentage of Participants With AEs, SAEs,MAEs and NDCMC Within 30 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that wasis expected to be persistent or otherwise long-lasting in its effects.
Time frame: Within 30 days after primary vaccination 2
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Any Primary Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that is was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Within 30 days after any primary vaccination
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Primary Series Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From day of primary vaccination 1 at Day 1 up to 1 month after primary vaccination 2
Percentage of Participants With SAEs, MAEs and NDCMC During Primary Series Follow-up Phase: Group 7 Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month after primary vaccination 2 up to booster vaccination
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Primary Series Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.
Time frame: From the date of primary vaccination 1 up to 8 months after primary vaccination 2 (maximum up to 9 months)
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
Time frame: Within 30 minutes After primary vaccination 1
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
Time frame: Within 30 minutes After primary vaccination 2
Percentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
Time frame: Within 30 minutes after booster vaccination
Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement.
Time frame: Within 7 Days after booster vaccination
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C, categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was graded as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.
Time frame: Within 7 days after booster vaccination
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From date of booster vaccination through 1 month after booster vaccination
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Follow-up Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 5 months)
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Booster Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 6 months)
hSBA Geometric Mean Titers (GMTs) for Each of the MenB Test Strains: 1 Month After Primary Vaccination 2 in Group 3 and 4 Combined Versus Group 5
GMTs were calculated by exponentiating mean logarithm of titers and CIs were calculated by exponentiating confidence limits based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 Month after primary Vaccination 2
hSBA GMTs for Each of the MenB Test Strains: 1 Month After Booster Vaccination in Groups 3, 4 and 5
GMTs were calculated by exponentiating the mean logarithm of the titers and CIs were calculated by exponentiating the confidence limits based on the Student t distribution for the mean logarithm of the titers. No serum samples were collected after booster dose for groups 4 and 5 due to study termination.
Time frame: 1 month after booster vaccination
Percentage of Participants With Local Reactions Within 7 Days After Each Primary Vaccination: Group 3, 4 and 5
Local reactions included pain at injection site, redness and swelling and were recorded by participant's in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site on left arm were reported in this outcome measure.
Time frame: Within 7 Days after primary Vaccination(Vac) 1 and 2
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Each Primary Vaccination: Group 3,4 and 5
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Exact 2-sided CI was based on the Clopper and Pearson method. Decreased appetite was categorized as Grade 1:decreased interest in eating, Grade 2:decreased oral intake, Grade3: refusal to feed. Drowsiness: Grade 1 Increased or prolonged sleeping bouts,Grade2: Slightly subdued interfering with daily activity, Grade3; Disabling, not interested in usual daily activity. Irritability; Grade1: Easily consolable, Grade2: requiring increased attention, Grade 3: Inconsolable; crying could not be comforted.
Time frame: Within 7 Days after primary Vaccination 1 and 2
Percentage of Participants With AEs, SAEs, MAEs and NDCMC: Groups 3, 4 and 5
Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.
Time frame: Within 30 days after any vaccination
| Milestone | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 23 | 25 | 36 | 16 | 53 | 50 | 55 | 55 | 12 |
| Primary vaccination 1 | 23 | 25 | 39 | 16 | 50 | 50 | 55 | 55 | 12 |
| Primary vaccination 2 | 22 | 25 | 23 | 16 | 50 | 42 | 54 | 55 | 0 |
| Booster vaccination | 22 | 25 | 22 | 4 | 9 | 0 | 47 | 45 | 0 |
| Completed | 22 | 25 | 20 | 0 | 2 | 0 | 25 | 22 | 0 |
| Not completed | 1 | 0 | 16 | 16 | 51 | 50 | 30 | 33 | 12 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 14 | 15 | 47 | 43 | 29 | 29 | 12 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 1 | 3 | 4 | 0 | 2 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 22 | 25 | 20 | 0 | 2 | 0 | 25 | 22 | 0 |
| Completed | 22 | 25 | 20 | 0 | 2 | 0 | 25 | 21 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Percentage of participants achieving hSBA titer greater than or equal to (\>=) lower limit of quantitation (LLOQ) (i.e.,1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided confidence interval (CI) using the Clopper and Pearson method was presented. Analysis was performed on Post-primary vaccination 2 (post-PV2) evaluable immunogenicity population (EIP). No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| MenA | 100.0 (79.4 to 100.0) | 100.0 (96.0 to 100.0) |
| MenC | 100.0 (79.4 to 100.0) | 100.0 (96.0 to 100.0) |
| MenW | 100.0 (79.4 to 100.0) | 100.0 (96.0 to 100.0) |
| MenY | 100.0 (79.4 to 100.0) | 100.0 (96.1 to 100.0) |
Percentage of participants achieving hSBA titer \>= LLOQ (1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| MenA | — | 100.0 (91.4 to 100.0) |
| MenC | — | 100.0 (91.4 to 100.0) |
| MenW | — | 100.0 (91.6 to 100.0) |
| MenY | — | 100.0 (91.4 to 100.0) |
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| PMB80 (A22) | 44.4 (21.5 to 69.2) | 9.6 (4.5 to 17.4) |
| PMB2707 (B44) | 88.9 (65.3 to 98.6) | 29.5 (20.6 to 39.7) |
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain(1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented.
| Percentage of participants | Group 3 and 4 Combined | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|
| PMB80 (A22) | 46.7 (28.3 to 65.7) | 47.7 (32.5 to 63.3) |
| PMB2707 (B44) | 82.9 (66.4 to 93.4) | 97.8 (88.2 to 99.9) |
Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| PMB80 (A22) | — | 25.0 (12.7 to 41.2) |
| PMB2707 (B44) | — | 34.1 (20.1 to 50.6) |
Percentage of participants achieving hSBA titer \>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. Groups 4 and 5 had no serum samples collected post-booster for serology testing due to study termination.
| Percentage of participants | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|---|
| PMB80 (A22) | 38.9 (17.3 to 64.3) | — | — |
| PMB2707 (B44) | 83.3 (58.6 to 96.4) | — | — |
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Redness: Mild | 22.6 (12.9 to 35.0) | 23.1 (15.6 to 32.2) |
| Redness: Moderate | 11.3 (4.7 to 21.9) | 6.5 (2.6 to 12.9) |
| Redness: Severe | 0 (0.0 to 5.8) | 0 (0.0 to 3.4) |
| Swelling: Mild | 21.0 (11.7 to 33.2) | 22.2 (14.8 to 31.2) |
| Swelling: Moderate | 17.7 (9.2 to 29.5) | 12.0 (6.6 to 19.7) |
| Swelling: Severe | 0 (0.0 to 5.8) | 0 (0.0 to 3.4) |
| Tenderness at injection site: Mild | 22.6 (12.9 to 35.0) | 25.9 (18.0 to 35.2) |
| Tenderness at injection site: Moderate | 48.4 (35.5 to 61.4) | 24.1 (16.4 to 33.3) |
| Tenderness at injection site: Severe | 0 (0.0 to 5.8) | 0.9 (0.0 to 5.1) |
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Group 7 | Group 8 and 10 Combined |
|---|---|---|
| Redness: Mild | 26.8 (14.2 to 42.9) | 27.1 (19.0 to 36.6) |
| Redness: Moderate | 12.2 (4.1 to 26.2) | 11.2 (5.9 to 18.8) |
| Redness: Severe | 0 (0.0 to 8.6) | 0 (0.0 to 3.4) |
| Swelling: Mild | 19.5 (8.8 to 34.9) | 25.2 (17.3 to 34.6) |
| Swelling: Moderate | 14.6 (5.6 to 29.2) | 12.1 (6.6 to 19.9) |
| Swelling: Severe | 0 (0.0 to 8.6) | 0 (0.0 to 3.4) |
| Tenderness at injection site: Mild | 22.0 (10.6 to 37.6) | 27.1 (19.0 to 36.6) |
| Tenderness at injection site: Moderate | 34.1 (20.1 to 50.6) | 23.4 (15.7 to 32.5) |
| Tenderness at injection site: Severe | 4.9 (0.6 to 16.5) | 2.8 (0.6 to 8.0) |
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 29.0 (18.2 to 41.9) | 15.7 (9.4 to 24.0) |
| Fever: >38.4°C to 38.9°C | 24.2 (14.2 to 36.7) | 5.6 (2.1 to 11.7) |
| Fever: >38.9°C to 40.0°C | 9.7 (3.6 to 19.9) | 0 (0.0 to 3.4) |
| Fever: >40.0°C | 0 (0.0 to 5.8) | 0 (0.0 to 3.4) |
| Decreased appetite: Mild | 17.7 (9.2 to 29.5) | 17.6 (10.9 to 26.1) |
| Decreased appetite: Moderate | 43.5 (31.0 to 56.7) | 21.3 (14.0 to 30.2) |
| Decreased appetite: Severe | 4.8 (1.0 to 13.5) | 0.9 (0.0 to 5.1) |
| Irritability: Mild | 21.0 (11.7 to 33.2) | 19.4 (12.5 to 28.2) |
| Irritability: Moderate | 59.7 (46.4 to 71.9) | 45.4 (35.8 to 55.2) |
| Irritability: Severe | 14.5 (6.9 to 25.8) | 6.5 (2.6 to 12.9) |
| Drowsiness: Mild | 37.1 (25.2 to 50.3) | 39.8 (30.5 to 49.7) |
| Drowsiness: Moderate | 32.3 (20.9 to 45.3) | 18.5 (11.7 to 27.1) |
| Drowsiness: Severe | 4.8 (1.0 to 13.5) | 0.9 (0.00 to 5.1) |
| Use of antipyretic medication | 46.8 (34.0 to 59.9) | 50.0 (40.2 to 59.8) |
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness was graded as Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Group 7 | Group 8 and 10 Combined |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 26.8 (14.2 to 42.9) | 31.8 (23.1 to 41.5) |
| Fever: >38.4°C to 38.9°C | 26.8 (14.2 to 42.9) | 14.0 (8.1 to 22.1) |
| Fever: >38.9°C to 40.0°C | 12.2 (4.1 to 26.2) | 2.8 (0.6 to 8.0) |
| Fever: >40.0°C | 0 (0.0 to 8.6) | 0 (0.0 to 3.4) |
| Decreased appetite: Mild | 22.0 (10.6 to 37.6) | 20.6 (13.4 to 29.5) |
| Decreased appetite: Moderate | 31.7 (18.1 to 48.1) | 25.2 (17.3 to 34.6) |
| Decreased appetite: Severe | 4.9 (0.6 to 16.5) | 3.7 (1.0 to 9.3) |
| Irritability: Mild | 12.2 (4.1 to 26.2) | 21.5 (14.1 to 30.5) |
| Irritability: Moderate | 53.7 (37.4 to 69.3) | 48.6 (38.8 to 58.5) |
| Irritability: Severe | 22.0 (10.6 to 37.6) | 6.5 (2.7 to 13.0) |
| Drowsiness: Mild | 29.3 (16.1 to 45.5) | 45.8 (36.1 to 55.7) |
| Drowsiness: Moderate | 34.1 (20.1 to 50.6) | 14.0 (8.1 to 22.1) |
| Drowsiness: Severe | 4.9 (0.6 to 16.5) | 0.9 (0.0 to 5.1) |
| Use of antipyretic medication | 41.5 (26.3 to 57.9) | 72.9 (63.4 to 81.0) |
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Medically attended adverse event (MAE) was defined as a nonserious AE that resulted in an evaluation at a medical facility. Newly diagnosed chronic medical condition (NDCMC) was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | 24.2 | 16.4 |
| SAEs | 4.8 | 0 |
| MAEs | 14.5 | 10.0 |
| NDCMCs | 0 | 0.9 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that wasis expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 | Group 8 and 10 Combined |
|---|---|---|
| AEs | 33.3 | 12.8 |
| SAEs | 2.4 | 0 |
| MAEs | 23.8 | 11.0 |
| NDCMC | 0 | 0.9 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that is was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | 40.3 | 24.5 |
| SAEs | 6.5 | 0 |
| MAEs | 29.0 | 16.4 |
| NDCMC | 0 | 0.9 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | 56.5 | 33.6 |
| SAEs | 6.5 | 1.8 |
| MAEs | 43.5 | 24.5 |
| NDCMC | 1.6 | 0.9 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 | Group 8 and 10 Combined |
|---|---|---|
| AEs | 17.1 | 18.3 |
| SAEs | 4.9 | 2.8 |
| MAEs | 12.2 | 15.6 |
| NDCMC | 0 | 0.9 |
Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | 59.7 | 40.0 |
| SAEs | 9.7 | 4.5 |
| MAEs | 45.2 | 30.0 |
| NDCMC | 1.6 | 1.8 |
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined | 0 | 0 |
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 7 | Group 8 and 10 Combined |
|---|---|---|
| Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined | 0 | 0 |
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Percentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined | — | 0 |
Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement.
| Participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Redness | — | 38 |
| Swelling | — | 35 |
| Tenderness at injection site | — | 63 |
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C, categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was graded as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| Fever: 38.0°C to 38.4°C | — | 19.8 (12.2 to 29.4) |
| Fever: >38.4°C to 38.9°C | — | 11.0 (5.4 to 19.3) |
| Fever: >38.9°C to 40.0°C | — | 4.4 (1.2 to 10.9) |
| Fever: >40.0°C | — | 0 (0.0 to 4.0) |
| Decreased appetite: Mild | — | 17.6 (10.4 to 27.0) |
| Decreased appetite: Moderate | — | 27.5 (18.6 to 37.8) |
| Decreased appetite: Severe | — | 2.2 (0.3 to 7.7) |
| Irritability: Mild | — | 22.0 (14.0 to 31.9) |
| Irritability: Moderate | — | 42.9 (32.5 to 53.7) |
| Irritability: Severe | — | 7.7 (3.1 to 15.2) |
| Drowsiness: Mild | — | 26.4 (17.7 to 36.7) |
| Drowsiness: Moderate | — | 18.7 (11.3 to 28.2) |
| Drowsiness: Severe | — | 1.1 (0.0 to 6.0) |
| Use of antipyretic medication | — | 63.7 (53.0 to 73.6) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | — | 27.2 |
| SAEs | — | 0 |
| MAEs | — | 92 |
| NDCMC | — | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | — | 17.4 |
| SAEs | — | 2.2 |
| MAEs | — | 15.2 |
| NDCMC | — | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 7 and 11 Combined | Group 8 and 10 Combined |
|---|---|---|
| AEs | — | 40.2 |
| SAEs | — | 2.2 |
| MAEs | — | 25.0 |
| NDCMC | — | 0 |
GMTs were calculated by exponentiating mean logarithm of titers and CIs were calculated by exponentiating confidence limits based on the Student t distribution for the mean logarithm of the titers.
| Titers | Group 3 and 4 Combined | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|
| PMB80 (A22) | 13.9 (10.8 to 18.0) | 15.3 (12.1 to 19.3) |
| PMB2707 (B44) | 25.0 (19.9 to 31.4) | 25.0 (19.9 to 31.4) |
GMTs were calculated by exponentiating the mean logarithm of the titers and CIs were calculated by exponentiating the confidence limits based on the Student t distribution for the mean logarithm of the titers. No serum samples were collected after booster dose for groups 4 and 5 due to study termination.
| Titers | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|---|
| PMB80 (A22) | 21.8 ± 11.1 | — | — |
| PMB2707 (B44) | 25.4 ± 12.6 | — | — |
Local reactions included pain at injection site, redness and swelling and were recorded by participant's in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site on left arm were reported in this outcome measure.
| Percentage of participants | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|---|
| Vaccination 1:Redness:Mild | 27.8 (14.2 to 45.2) | 18.8 (4.0 to 45.6) | 13.2 (5.5 to 25.3) |
| Vacc1Redness:Moderate | 8.3 (1.8 to 22.5) | 0 (0.0 to 20.6) | 3.8 (0.5 to 13.0) |
| Vacc1Redness: Severe | 0 (0.0 to 9.7) | 0 (0.0 to 20.6) | 0 (0.0 to 6.7) |
| Vacc1:Swelling: Mild | 16.7 (6.4 to 32.8) | 6.3 (0.2 to 30.2) | 9.4 (3.1 to 20.7) |
| Vacc1:Swelling: Moderate | 11.1 (3.1 to 26.1) | 12.5 (1.6 to 38.3) | 5.7 (1.2 to 15.7) |
| Vacc1:Swelling: Severe | 0 (0. to 9.7) | 0 (0.0 to 20.6) | 0 (0.0 to 6.7) |
| Vac1Tenderness at inj.site:Mild | 19.4 (8.2 to 36.0) | 12.5 (1.6 to 38.3) | 22.6 (12.3 to 36.2) |
| Vac1Tenderness at inj.site: Moderate | 41.7 (25.5 to 59.2) | 18.8 (4.0 to 45.6) | 20.8 (10.8 to 34.1) |
| Vac1Tenderness at inj.site: Severe | 0 (0.0 to 9.7) | 0 (0.0 to 20.6) | 1.9 (0.0 to 10.1) |
| Vac2Redness: Mild | 33.3 (14.6 to 57.0) | 18.8 (4.0 to 45.6) | 19.2 (9.6 to 32.5) |
| Vac2Redness: Moderate | 4.8 (0.1 to 23.8) | 0 (0.0 to 20.6) | 3.8 (0.5 to 13.2) |
| Vac2Redness: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 20.6) | 0 (0.0 to 6.8) |
| Vac2Swelling: Mild | 19.0 (5.4 to 41.9) | 12.5 (1.6 to 38.3) | 9.6 (3.2 to 21.0) |
| Vac2Swelling: Moderate | 0 (0.0 to 16.1) | 12.5 (1.6 to 38.3) | 1.9 (0.0 to 10.3) |
| Vac2Swelling Severe | 0 (0.0 to 16.1) | 0 (0.0 to 20.6) | 0 (0.0 to 6.8) |
| Vac2Tenderness at inj.site Mild | 28.6 (11.3 to 52.2) | 12.5 (1.6 to 38.3) | 32.7 (20.3 to 47.1) |
| Vac2Tenderness at inj.siteModerate | 9.5 (1.2 to 30.4) | 18.8 (4.0 to 45.6) | 17.3 (8.2 to 30.3) |
| Vac2Tenderness at inj.siteSevere | 0 (0.0 to 16.1) | 6.3 (0.2 to 30.2) | 1.9 (0.0 to 10.3) |
Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Exact 2-sided CI was based on the Clopper and Pearson method. Decreased appetite was categorized as Grade 1:decreased interest in eating, Grade 2:decreased oral intake, Grade3: refusal to feed. Drowsiness: Grade 1 Increased or prolonged sleeping bouts,Grade2: Slightly subdued interfering with daily activity, Grade3; Disabling, not interested in usual daily activity. Irritability; Grade1: Easily consolable, Grade2: requiring increased attention, Grade 3: Inconsolable; crying could not be comforted.
| Percentage of participants | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|---|
| Vac1Fever38.0°C to 38.4°C | 30.6 (16.3 to 48.1) | 18.8 (4.0 to 45.6) | 35.8 (23.1 to 50.2) |
| Vac1Fever>38.4°C to 38.9°C | 27.8 (14.2 to 45.2) | 6.3 (0.2 to 30.2) | 17.0 (8.1 to 29.8) |
| Vac1Fever>38.9°C to 40.0°C | 0 (0.0 to 9.7) | 0 (0.0 to 20.6) | 11.3 (4.3 to 23.0) |
| Vac1Fever >40.0°C | 0 (0.0 to 9.7) | 0 (0.0 to 20.6) | 0 (0.0 to 6.7) |
| Vac1Decreased appetite Mild | 25.0 (12.1 to 42.2) | 6.3 (0.2 to 30.2) | 28.3 (16.8 to 42.3) |
| Vac1Decreased appetite Moderate | 22.2 (10.1 to 39.2) | 43.8 (19.8 to 70.1) | 34.0 (21.5 to 48.3) |
| Vac1Decreasedappetite Severe | 2.8 (0.1 to 14.5) | 0 (0.0 to 20.6) | 3.8 (0.5 to 13.0) |
| Vac1IrritabilityMild | 16.7 (6.4 to 32.8) | 6.3 (0.2 to 30.2) | 5.7 (1.2 to 15.7) |
| Vac1IrritabilityModerate | 58.3 (40.8 to 74.5) | 75.0 (47.6 to 92.7) | 58.5 (44.1 to 71.9) |
| Vac1IrritabilitySevere | 8.3 (1.8 to 22.5) | 6.3 (0.22 to 30.2) | 13.2 (5.5 to 25.3) |
| Vac1DrowsinessMild | 36.1 (20.8 to 53.8) | 37.5 (15.2 to 64.6) | 49.1 (35.1 to 63.2) |
| Vac1DrowsinessModerate | 33.3 (18.6 to 51.0) | 31.3 (11.0 to 58.7) | 39.6 (26.5 to 54.0) |
| Vac1DrowsinessSevere | 2.8 (0.1 to 14.5) | 0 (0.0 to 20.6) | 3.8 (0.5 to 13.0) |
| Use of antipyretic medication | 58.3 (40.8 to 74.5) | 56.3 (29.9 to 80.2) | 83.0 (70.2 to 91.9) |
| Vac2 >38.0°C to 38.4°C | 23.8 (8.2 to 47.2) | 25.0 (7.3 to 52.4) | 28.8 (17.1 to 43.1) |
| Vac2 >>38.4°C to 38.9°C | 23.8 (8.2 to 47.2) | 25.0 (7.3 to 52.4) | 25.0 (14.0 to 38.9) |
| Vac2>>38.9°C to 40.0°C | 4.8 (0.1 to 23.8) | 0 (0.0 to 20.6) | 13.5 (5.6 to 25.8) |
| Vac2>40.0°C | 0 (0.0 to 16.1) | 0 (0.0 to 20.6) | 0 (0.0 to 6.8) |
| Vac2Decreased appetiteMild | 4.8 (0.1 to 23.8) | 6.3 (0.2 to 30.2) | 28.8 (17.1 to 43.1) |
| Vac2Decreased appetiteModerate | 28.6 (11.3 to 52.2) | 50.0 (24.7 to 75.3) | 38.5 (25.3 to 53.0) |
| Vac2Decreased appetite Severe | 4.8 (0.1 to 23.8) | 6.3 (0.2 to 30.2) | 5.8 (1.2 to 15.9) |
| Vac2 Irritability Mild | 28.6 (11.3 to 52.2) | 12.5 (1.6 to 38.3) | 21.2 (11.1 to 34.7) |
| Vac2IrritabilityModerate | 23.8 (8.2 to 47.2) | 68.8 (41.3 to 89.0) | 48.1 (34.0 to 62.4) |
| Vac2IrritabilitySevere | 4.8 (0.1 to 23.8) | 0 (0.0 to 20.6) | 9.6 (3.2 to 21.0) |
| Vac2DrowsinessMild | 47.6 (25.7 to 70.2) | 43.8 (19.8 to 70.1) | 40.4 (27.0 to 54.9) |
| Vac2DrowsinessModertae | 23.8 (8.2 to 47.2) | 12.5 (1.6 to 38.3) | 28.8 (17.1 to 43.1) |
| Vac2DrowsinessSevere | 0 (0.0 to 16.1) | 0 (0.0 to 20.6) | 3.8 (0.5 to 13.2) |
| Vac2Use of antipyretic medication | 81.0 (58.1 to 94.6) | 87.5 (61.7 to 98.4) | 86.5 (74.2 to 94.4) |
Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.
| Percentage of participants | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) |
|---|---|---|---|
| AEs | 52.8 | 68.8 | 60.4 |
| SAEs | 2.8 | 6.3 | 20.8 |
| MAEs | 47.2 | 62.5 | 47.2 |
| NDCMC | 0 | 6.3 | 0 |
Collected over Systematic assessment(SA): local reactions/systemic events within 7 days after vaccination 1, 2 and booster vaccination; Non-systematic assessment: SAEs and other AEs from Day 1 up to 196 days after last study vaccination (up to 12 months for Group1 and 2; up to 16 months for Group 3,4,5,7,8,10,11). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (MenABCWY +PLP) | 0/23 (0%) | 0/23 (0%) | 23/23 (100%) |
| Group 2 (MenABCWY) | 0/25 (0%) | 1/25 (4%) | 25/25 (100%) |
| Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | 0/36 (0%) | 1/36 (2.8%) | 36/36 (100%) |
| Group 4 (60 mcg rLP2086 +Nimenrix) | 0/16 (0%) | 1/16 (6.3%) | 16/16 (100%) |
| Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | 0/53 (0%) | 11/53 (20.8%) | 53/53 (100%) |
| Group 7 (MenABCWY +SLP) | 1/50 (2%) | 5/50 (10%) | 50/50 (100%) |
| Group 8 (Bexsero +Nimenrix +PLP) | 0/55 (0%) | 1/55 (1.8%) | 54/55 (98.2%) |
| Group 10 (Bexsero +Nimenrix) | 0/55 (0%) | 6/55 (10.9%) | 55/55 (100%) |
| Group 11 (MenABCWY +TLP) | 0/12 (0%) | 1/12 (8.3%) | 12/12 (100%) |
| Event | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) |
|---|---|---|---|---|---|---|---|---|---|
| Meningitis bacterialInfections and infestations | 0/23 | 0/25 | 0/36 | 0/16 | 0/53 | 0/50 | 0/55 | 0/55 | 1/12 |
| BronchiolitisInfections and infestations | 0/23 | 0/25 | 0/36 | 1/16 | 2/53 | 2/50 | 0/55 | 0/55 | 0/12 |
| PapilloedemaEye disorders | 0/23 | 1/25 | 0/36 | 0/16 | 0/53 | 0/50 | 0/55 | 0/55 | 0/12 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/23 | 0/25 | 0/36 | 0/16 | 2/53 | 1/50 | 0/55 | 0/55 | 0/12 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 0/23 | 0/25 | 0/36 | 0/16 | 0/53 | 0/50 | 1/55 | 2/55 | 0/12 |
| LymphadenitisBlood and lymphatic system disorders | 0/23 | 0/25 | 1/36 | 0/16 | 0/53 | 0/50 | 0/55 | 0/55 | 0/12 |
| Sudden infant death syndromeGeneral disorders | 0/23 | 0/25 | 0/36 | 0/16 | 0/53 | 1/50 | 0/55 | 0/55 | 0/12 |
| Escherichia urinary tract infectionInfections and infestations | 0/23 | 0/25 | 0/36 | 0/16 | 0/53 | 1/50 | 0/55 | 0/55 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/23 | 0/25 | 0/36 | 0/16 | 1/53 | 0/50 | 0/55 | 0/55 | 0/12 |
| COVID-19Infections and infestations | 0/23 | 0/25 | 0/36 | 0/16 | 1/53 | 0/50 | 0/55 | 1/55 | 0/12 |
| Event | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) |
|---|---|---|---|---|---|---|---|---|---|
| Irritability (IRRITABILITY)Psychiatric disorders | 22/23 | 20/25 | 32/36 | 14/16 | 50/53 | 49/50 | 44/55 | 49/55 | 12/12 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 18/23 | 18/25 | 32/36 | 12/16 | 50/53 | 39/50 | 44/55 | 43/55 | 10/12 |
| Tenderness (TENDERNESS)General disorders | 20/23 | 20/25 | 23/36 | 8/16 | 35/53 | 41/50 | 41/55 | 45/55 | 8/12 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 18/23 | 17/25 | 25/36 | 11/16 | 46/53 | 38/50 | 37/55 | 41/55 | 9/12 |
| Pyrexia (FEVER)General disorders | 15/23 | 19/25 | 25/36 | 10/16 | 42/53 | 38/50 | 32/55 | 39/55 | 7/12 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 8/23 | 13/25 | 18/36 | 6/16 | 19/53 | 22/50 | 31/55 | 35/55 | 4/12 |
| Swelling (SWELLING)General disorders | 10/23 | 14/25 | 13/36 | 5/16 | 10/53 | 26/50 | 30/55 | 31/55 | 2/12 |
| GastroenteritisInfections and infestations | 6/23 | 8/25 | 2/36 | 0/16 | 1/53 | 1/50 | 4/55 | 4/55 | 0/12 |
| Hand-foot-and-mouth diseaseInfections and infestations | 0/23 | 7/25 | 0/36 | 0/16 | 0/53 | 0/50 | 3/55 | 0/55 | 0/12 |
| PyrexiaGeneral disorders | 6/23 | 2/25 | 2/36 | 0/16 | 4/53 | 4/50 | 3/55 | 5/55 | 0/12 |
Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination.
| Age, Continuous(Days) | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 158.5 ± 6.87 | 161.6 ± 14.45 | 71.1 ± 7.00 | 67.6 ± 5.81 | 68.9 ± 6.39 | 68.0 ± 5.99 | 67.4 ± 7.89 | 67.5 ± 7.30 | 69.4 ± 7.69 | 81.9 ± 33.51 |
| Sex: Female, Male(Participants) | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 10 | 21 | 7 | 24 | 27 | 32 | 20 | 7 | 160 |
| Male | 11 | 15 | 15 | 9 | 29 | 23 | 23 | 35 | 5 | 165 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 9 | 21 | 8 | 10 | 25 | 18 | 22 | 6 | 132 |
| Not Hispanic or Latino | 10 | 16 | 15 | 8 | 43 | 25 | 37 | 33 | 6 | 193 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1 (MenABCWY +PLP) | Group 2 (MenABCWY) | Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP) | Group 4 (60 mcg rLP2086 +Nimenrix) | Group 5 (120 mcg rLP2086 +Nimenrix +PLP) | Group 7 (MenABCWY +SLP) | Group 8 (Bexsero +Nimenrix +PLP) | Group 10 (Bexsero +Nimenrix) | Group 11 (MenABCWY +TLP) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| White | 20 | 24 | 35 | 16 | 52 | 50 | 55 | 55 | 12 | 319 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2020 to primary completion in Sep 2022, 21 months.
Results were first posted in Mar 2024, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meningococcal pentavalent vaccine · 4CMenB vaccine